Eindhoven, Netherlands – May 19, 2026 – ONWARD Medical, a leading neurotechnology company based in Eindhoven, has announced the successful completion of a financing round, securing €40.6 million. This substantial capital infusion is earmarked to significantly advance the company's critical Empower BP pivotal trial, which is currently evaluating the efficacy of its innovative implantable ARC-IM® system. The system aims to treat blood pressure instability, a significant and debilitating complication often experienced by individuals following spinal cord injuries.
The financing underscores a strong investor confidence in ONWARD's pioneering approach to neurological conditions. The ARC-IM® system represents a notable development in neurorehabilitation, leveraging targeted spinal cord stimulation to address autonomic dysfunctions that can severely impact the quality of life for spinal cord injury patients. Blood pressure instability, specifically, can lead to dangerous episodes of hypotension or hypertension, posing serious health risks and complicating rehabilitation efforts.
Advancing the Empower BP Pivotal Trial
The primary objective of this fundraising round is to channel resources directly into the Empower BP pivotal trial. This trial is a crucial step toward obtaining regulatory approval for the ARC-IM® system. Pivotal trials are typically large-scale, multi-center studies designed to demonstrate definitive evidence of a device's safety and effectiveness. By funding this trial, ONWARD is moving closer to making a significant impact on an underserved patient population.
Spinal cord injuries often disrupt the autonomic nervous system, which controls involuntary bodily functions such as blood pressure regulation, heart rate, and digestion. This disruption can result in a condition known as autonomic dysreflexia or other forms of dysregulation, leading to unpredictable and potentially life-threatening fluctuations in blood pressure. Current treatments for these conditions are often palliative or symptom-managing, with limited options to restore underlying function. The ARC-IM® system offers a potential paradigm shift by directly modulating neural pathways.
The ARC-IM® System: A Technological Overview
ONWARD Medical's ARC-IM® system operates on the principle of targeted spinal cord stimulation (tSCS). This involves implanting electrodes near the spinal cord and delivering precise electrical pulses to specific neural pathways. The aim is to restore or improve the communication between the brain and the body below the injury level, thereby re-establishing better control over autonomic functions, including blood pressure.
The technology builds on years of research in neurostimulation and spinal cord injury recovery. Beyond blood pressure regulation, similar stimulation techniques are being explored for motor function restoration in paralysis. The success of the Empower BP trial could therefore have broader implications for the development of neurotechnologies addressing a range of post-injury complications, potentially opening new avenues for treatment in neurorehabilitation.
Broader Market and Industry Implications
The successful financing round positions ONWARD Medical as a significant player in the rapidly evolving neurotechnology sector. The market for implantable neurostimulation devices is projected to grow substantially as technological advancements improve efficacy and expand application areas. Addressing a critical unmet need in spinal cord injury care, the ARC-IM® system has the potential to carve out a distinct and valuable niche within this market.
This investment also signals a strong interest from the financial community in solutions that improve long-term outcomes for patients with chronic neurological conditions. As healthcare systems increasingly focus on reducing rehospitalizations and improving quality of life, technologies that offer restorative rather than merely symptomatic relief are becoming increasingly attractive. The outcome of the Empower BP trial will be closely watched by clinicians, investors, and patient advocates alike, as it could reshape the standard of care for blood pressure instability after spinal cord injury.
What Lies Ahead for ONWARD Medical
With the secured funding, ONWARD Medical will now accelerate the enrollment and progression of its Empower BP pivotal trial. The execution and eventual results of this trial will be paramount in determining the regulatory pathway and commercial viability of the ARC-IM® system. Successful completion of the trial and subsequent regulatory approvals would allow ONWARD to bring this potentially life-changing technology to a global patient population.
Beyond the Empower BP trial, the company's research pipeline may also explore other applications of its ARC technology for various neurological impairments. The strategic investment in this flagship trial underscores ONWARD Medical's commitment to innovation in neurorehabilitation, aiming to provide solutions that significantly improve the independence and overall health of individuals living with spinal cord injuries.